黑人与白人女性子宫肌层与平滑肌瘤转录组学及活性氧负荷的种族差异
研究比较黑人女性与白人女性子宫肌层和平滑肌瘤中MED12突变、转录组学及蛋白表达的差异。RNA测序、组织芯片和免疫组化显示两族群在肌层和平滑肌瘤特征上存在显著差异,黑人女性平滑肌瘤MED12突变率更高。
要点
- 黑人女性平滑肌瘤MED12突变率为79.0%,高于白人女性的68.5%(P≤0.05)。
- RNA测序显示肌层中活性氧、缺氧和氧化磷酸化通路与黑人患者样本正相关。
- 8-OHdG、OGG1、HO-1和KEAP1蛋白在平滑肌瘤及配对肌层中更高,黑人患者尤为明显(P≤0.001)。
核心结论
- RNA测序、组织芯片和免疫组化数据揭示黑人女性与白人女性在肌层和平滑肌瘤特征上存在显著差异。
研究设计与样本
- 子宫组织取自2010年至2021年在西北大学普伦蒂斯妇女医院(芝加哥,伊利诺伊州)接受子宫切除术或子宫肌瘤切除术的绝经前女性。
- 组织共来自309名女性,包括136名黑人女性、135名白人女性和38名其他种族女性。
- 共529个子宫平滑肌瘤(290个来自黑人女性,184个来自白人女性,55个来自其他种族女性)进行分子分析。
- 共118例(60名黑人女性和58名白人女性)的平滑肌瘤及配对肌层用于组织芯片,另加34份来自白人女性的无平滑肌瘤肌层样本。
- 组织通过组织芯片、免疫组化、RNA测序和突变分析进行分析。
主要发现
- 黑人女性平滑肌瘤MED12突变率为79.0%,高于白人女性的68.5%(P≤0.05)。
- 肌层RNA测序显示种族依赖的差异表达基因(270个上调,374个下调),活性氧、缺氧和氧化磷酸化通路与黑人患者样本正相关。
- 氧化DNA损伤和修复相关蛋白8-OHdG、OGG1、HO-1和KEAP1在平滑肌瘤及配对肌层中水平更高,黑人患者尤为明显,与对照肌层(含平滑肌瘤)相比(P≤0.001)。
临床怎么用
- 有症状平滑肌瘤女性生活质量显著下降,本研究提供可能对未来靶向治疗必要的遗传和分子缺陷信息。
局限性
- 组织芯片分析中无平滑肌瘤的白人患者肌层用作对照,因为黑人患者无平滑肌瘤肌层无法大量获取。
- RNA测序在10名白人女性和10名黑人女性的含平滑肌瘤肌层组织上进行,但一名黑人女性样本RNA测序数据质量低被排除进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there differences in Mediator Complex Subunit 12 mutations (MED12) mutation, transcriptomics, and protein expression in uterine myometrium and leiomyomas of Black and White women? SUMMARY ANSWER: RNA sequencing, tissue microarray, and immunohistochemistry data revealed that Black and White women have significant differences in their myometrium and leiomyoma profiles. WHAT IS KNOWN ALREADY: Black women develop uterine leiomyoma earlier than White women, and are more likely to be anemic, have multiple tumors, undergo hysterectomy at an earlier age, have a higher uterine weight, and report very severe pelvic pain. STUDY DESIGN, SIZE, DURATION: Uterine tissues were collected from premenopausal women undergoing hysterectomy or myomectomy at Northwestern University Prentice Women's Hospital (Chicago, IL) from 2010 to 2021. Tissues were collected from a total of 309 women, including from 136 Black women, 135 White women, and 38 women from other racial groups. A total of 529 uterine leiomyomas (290 from Black women, 184 from White women, and 55 from women of other racial groups) were subjected to molecular analysis. Leiomyoma and matched myometrium from a total of 118 cases including 60 Black women and 58 White women, were used for tissue microarrays, along with 34 samples of myometrium without leiomyoma from White women. PARTICIPANTS/MATERIALS, SETTING, METHODS: Tissues from the above patient cohorts were analyzed by tissue microarray, immunohistochemistry, RNA sequencing, and mutation analysis. MAIN RESULTS AND THE ROLE OF CHANCE: The results indicated that leiomyoma from Black women have a higher rate of MED12 mutations (79.0%) than those from White women (68.5%) (*P ≤ 0.05). RNA-sequencing analysis in myometrium revealed differentially expressed genes (270 upregulated, 374 downregulated) dependent on race, wherein reactive oxygen species, hypoxia, and oxidative phosphorylation pathways were positively correlated with samples derived from Black patients. The levels of proteins associated with oxidative DNA damage and repair, 8-hydroxyguanosine (8-OHdG), 8-oxoguanine glycosylase (OGG1), heme oxygenase-1 (HO-1), and kelch-like ECH-associated protein 1 (KEAP1), were higher in leiomyoma and matched myometrium, particularly those from Black patients, compared to the control myometrium (with leiomyoma) (***P ≤ 0.001). LARGE SCALE DATA: The datasets are available in the NCBI (The BioProject number: PRJNA859428). LIMITATIONS, REASONS FOR CAUTION: Myometrium without leiomyoma derived from White patients was used as a control in the tissue microarray analysis, as myometrium without leiomyoma from Black patients was not accessible in large numbers. The RNA sequencing was performed on myometrium tissue with leiomyoma present from 10 White and 10 Black women. However, one sample from a Black woman yielded low-quality RNA-sequencing data and was excluded from further analysis. WIDER IMPLICATIONS OF THE FINDINGS: Women with symptomatic leiomyomas have a considerable loss in their quality of life. This study provides information on underlying genetic and molecular defects that may be necessary for future therapeutics targeted at leiomyomas. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by grants from NCI (R01CA254367) and NICHD (P01HD057877). The authors declare no conflict of interest.
引用
- Li Y, McNally RP, Feng Y, et al. Racial differences in transcriptomics and reactive oxygen species burden in myometrium and leiomyoma. Hum Reprod. 2023. PMID: 36749068. doi:10.1093/humrep/dead020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。